Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy

Autor:	Matt Weinstock, Pavania Elavalakanar, Susan Bright, Srikanth R. Ambati, Jurriaan Brouwer‐Visser, Stephane Pourpe, Nathalie Fiaschi, Vladimir Jankovic, Gavin Thurston, Raquel P. Deering, Aafia Chaudhry, Robin Joyce, Jon Arnason
Rok vydání:	2022
Předmět:	Receptors Chimeric Antigen Antigens CD19 Antibodies Bispecific Cell- and Tissue-Based Therapy Receptors Antigen T-Cell Humans Antineoplastic Agents Hematology Lymphoma Large B-Cell Diffuse Neoplasm Recurrence Local Cytokine Release Syndrome Immunotherapy Adoptive Lymphoma Follicular
Zdroj:	British journal of haematologyREFERENCES. 199(3)
ISSN:	1365-2141
Popis:	Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for ≥2 years following odronextamab. Neither patient experienced Grade ≥3 cytokine release syndrome or Grade ≥3 neurological adverse events during treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974fa49fc9d8c7442fbf070f23a20c65 https://pubmed.ncbi.nlm.nih.gov/35892294 Zobrazit plný text záznamu Plný text